Team

Making a positive difference to patient experiences and mental health outcomes requires collaboration across disciplines. Our leadership team and actively engaged board, advisors, and investors are committed to integrating their diverse expertise in service to patients, their families, and society.

Core COMPASS team

Ekaterina Malievskaia

Ekaterina Malievskaia MD MScPH

Chief Innovation Officer and Co-Founder

Dr Ekaterina Malievskaia leads Research and Development at COMPASS.

Ekaterina received her medical degree from St Petersburg Medical Academy in St Petersburg, Russia. After her Internal Medicine residency training, she completed an Environmental Medicine Fellowship at Mount Sinai School of Medicine and received her MSc in Public Health from New York University Medical School. She worked in private practice, academic medicine and public health for more than 15 years in the greater New York area. She was a Clinical Instructor of Medicine at Mount Sinai School of Medicine, as well as a Research Professor at City University of New York.

After moving to London in 2011, Ekaterina worked in global health and medical philanthropy, focusing on improving outcomes in maternal and child health. She founded COMPASS Pathways with her husband George Goldsmith in 2016, having experienced at first hand the challenges in accessing evidence-based and effective mental health care for a family member.

We have created COMPASS to improve patients’ access to innovation in mental health. Through our personal experiences, we have learned how challenging it could be to find the right treatment and right expertise in time. We also learned that it could make all the difference in the outcomes. We walked that path so others don’t have to.

George Goldsmith

George Goldsmith

Executive Chairman, Chief Executive Officer and Co-Founder

George is an entrepreneur dedicated to bringing about positive change in society with particular focus on health and wellbeing.

George's early training and experience was a multi-disciplinary blending of cognitive psychology, clinical psychology and computer science. His first company, The Human Interface Group, was a pioneer in collaborative software and acquired by Lotus Development. George led the Lotus Institute and developed software and services to support high-performance, distributed teamwork. George then created TomorrowLab, which provided strategic guidance to internet businesses in the late 1990s. At the same time, he became a senior advisor to McKinsey & Company’s leadership, and eventually joined McKinsey as CEO of TomorrowLab@McKinsey. Subsequently, as a member of the Young Presidents Organisation (YPO) and its International Board of Directors, George founded YPO Networks. In 2002, George founded Tapestry Networks, an organisation committed to improving leadership performance and governance effectiveness in regulated sectors. He still serves as Tapestry Networks' Non-Executive Chairman. George also serves on the board of directors for AnaBios, a company redefining drug discovery. He and his wife, Ekaterina Malievskaia MD, live in London.

I have spent my life working with teams of leaders seeking to do extraordinary things. The best of them fight the tendency to accept zero-sum strategies and declare victory. They understand that we can create environments where people suspend disbelief, build trust and chase unlikely combinations of new ideas and technologies.

Lars Wilde

Lars Christian Wilde

President, Chief Business Officer and Co-Founder

Lars is President, Chief Business Officer and Co-Founder of COMPASS Pathways.

Lars is an active serial entrepreneur in tech and biotech and business angel, and has helped to successfully build several companies. Before joining COMPASS, Lars was the founder and CEO of Springlane, a leading European direct to consumer kitchen and BBQ brand and the largest German cooking magazine. Lars previously worked as an investor at Waterland Private Equity, one of the world’s best performing private equity funds. Amongst other buy-and-build investments, he focused on building VivaNeo, the largest European in-vitro fertilization group, providing patients with cutting edge medical solutions. Lars has also spent time with Boston Consulting Group in Munich and São Paulo. Lars holds a master's degree in Finance from IE Business School in Spain and a Bachelor of Science in Business Administration from Rotterdam School of Management, Erasmus University in the Netherlands. He spent exchange semesters at the University of Münster, the Copenhagen Business School and the Ross School of Business at the University of Michigan.

Having suffered from treatment-resistant depression and generalized anxiety disorder myself, I understand the devastating impact the diseases have on a person’s life. I had the privilege of accessing a treatment with psilocybin and have been relieved of the debilitating diseases ever since. Unfortunately, this treatment is not legally available to most people in the world and its efficacy has yet to be proven in large-scale clinical trials. Having founded and invested in several companies in the past, I recognised that COMPASS offers the opportunity to build something immensely beneficial for our global society. I am excited by the outlook of solving one of humanity’s largest unmet medical needs together with an extremely smart and vision-driven team.

Hans Eriksson

Hans Eriksson

Chief Medical Officer

Hans is Chief Medical Officer of COMPASS Pathways, leading the clinical development programme.

Hans gained his MD and did his residency in psychiatry at Lund University in Sweden. He also holds a PhD in Cell and Molecular Biology from Lund University, and an executive MBA from Stockholm School of Economics. After having worked as consultant psychiatrist and assisting head of the Psychiatric Centre at Lund University Hospital, he moved to the pharmaceutical industry in 2000. He has been working in different roles with H. Lundbeck and AstraZeneca, especially on the development programmes for escitalopram, quetiapine XR, mecamylamine, and brexpiprazole for major depressive disorder, and for additional psychiatric indications. He had an active role in the successful regulatory submissions of Cipralex, Seroquel XR and Rexulti. He was the global medical lead for Seroquel XR at AstraZeneca, and in his most recent role he was Senior Director and head of clinical development for depression and paediatrics at H. Lundbeck. At COMPASS Pathways, Hans uses his clinical expertise and clinical development experience to lead the development programme.

It is a truly meaningful effort to participate in the development of a novel treatment paradigm for people suffering from severe mental disorders.

Joe Heinen

Joe Heinen

Chief Financial Officer

Joe is a senior finance professional with over 15 years of experience working with entrepreneurs to establish and lead early-stage companies in the US and Europe.

Joe has been working with COMPASS from the beginning. He is responsible for the financial operations of the firm. Joe is also the CFO of Tapestry Networks, a Boston-based professional services firm focused on helping leaders of some of the world’s most important institutions do their work more effectively and with greater confidence. Prior to Tapestry and COMPASS, Joe worked as an independent consultant offering CFO services to early-stage companies and, before that, he worked in fixed income sales and trading with Goldman Sachs in New York. Joe earned an undergraduate degree in engineering from the University of Wisconsin and a master’s degree in finance from the Kellogg School of Management.

I‘ve known George and Katya for years, and their passion for building an organisation that could one day provide access to this innovative therapy for millions of patients suffering from debilitating mental illness was contagious. I knew early on that I wanted to be on this journey with them.

Marco Mohwinckel

Marco Mohwinckel

Chief Commercial Officer

Marco is Chief Commercial Officer at COMPASS Pathways, leading on commercial strategy.

Throughout his career, Marco has been an outspoken advocate for change, innovation and entrepreneurship in healthcare. Over the past 15 years he led strategy and commercial operations for digital and pharmaceutical companies across various therapeutic areas and continents. Most recently he was VP of Strategy at WebMD / Medscape, the leading online health information platform for consumers and healthcare professionals; previously he worked at Johnson & Johnson as Global Head of Janssen Healthcare Innovation, where he was part of the Global Commercial Strategy Leadership Team, and as head of the Neuroscience Business Unit in the UK. As a management consultant at the Monitor Group, he advised life sciences and technology companies on growth strategies, market access, product launches, operational excellence, business development and strategic partnerships. Marco is an active advisor and independent board member in several health-tech start-ups and digital health networks. He engages in public speaking on digital health innovation and has co-authored several articles, most notably “Beyond magic bullets: True Innovation in Healthcare” (Nature Reviews Drug Discovery, 2013), arguing for the need to develop holistic solutions and new business models for patients suffering with mental illnesses.

In the next few years, we will see significant breakthroughs in the treatment of many 'silent' and debilitating mental health conditions, like depression, which affect millions of people around us. Having worked in this field for years, I am excited to be part of COMPASS on a pioneering mission to build and cross bridges that lead to a better future; one without prejudice or stigma, where empowered individuals have universal access to the best possible treatment and support.

Tracy Cheung

Tracy Cheung

Chief Communications Officer

Tracy Cheung has more than 25 years’ experience in strategic communications, working with senior executive teams on public affairs, investor and media relations, corporate communications, marketing communications, and employee engagement.

Tracy began her career in communications consultancy, working at Rowland Sallingbury Casey and Brunswick. She has since led communications teams in a number of healthcare and life sciences organisations, including Amersham International, GE Healthcare Medical Diagnostics, and Essentia (part of Guy’s and St Thomas’ NHS Foundation Trust). Tracy is also a coach with Parent Gym, an evidence-based philanthropic programme designed to support parents in raising happy and confident children.  

What I love about COMPASS is the absolute commitment to putting patients at the centre of everything we do, and the determination to help those suffering with mental illness.

Steve DiPalma

Interim CFO

Steve has more than 30 years of experience in life sciences and healthcare, including founding two start-ups and extensive work with venture-backed companies and publicly traded companies in the US and elsewhere in the world.

Steve is a partner and Managing Director at Danforth Advisors, a financial consultancy focused exclusively on life science companies. He has served as CFO for a number of public companies, both as a consultant and in a full-time role prior to joining Danforth, and has extensive experience in international fundraising and corporate structuring. Steve’s core expertise includes operational management, strategic planning and corporate and business development, fundraising and mergers and acquisitions. He holds a BS from the University of Massachusetts and MBA from Babson College.

I’m very excited to be working with the Compass team, and am deeply impressed with their passion and commitment to such an important mission. The team’s focus on the patient comes through in everything they do, and I’m very thankful for the opportunity to be involved with this extraordinary group of people.

Nate Poulsen

Nate Poulsen

General Counsel and Head of Legal, Intellectual Property, and Licensing

Nate focuses on global legal and IP strategy and initiatives.

Nate has more than 20 years of experience working in pharmaceuticals, combining science, business, and law. Nate has undergraduate degrees in mathematics, physics, and chemistry. As a student, Nate worked with Dr Alexander Shulgin, and was an American Society of Pharmacology and Experimental Therapeutics student fellow, researching amphetamine neurotoxicology with the acting director of the National Institute on Drug Abuse. Nate began his graduate work at Columbia University, where he studied under Dr David Sulzer, a leader in the field of neurotransmitter release and reuptake. He transitioned from research to business, earning his MBA from Cornell University's Johnson School of Management. Prior to beginning his legal career in 2006, Nate worked as a medicinal chemist for NPS Pharmaceuticals and as a researcher in the Department of Neurology at Columbia Presbyterian Medical Center. He also consulted on strategy in the medical device and consumer healthcare industries. Prior to joining COMPASS, Nate was a lawyer with Cooley LLP, where he represented and counselled clients on a wide variety of legal issues. While in private practice, he leveraged his diverse experience and education to develop and implement practical, efficient strategies for protecting, defending, and monetising innovations. Nate is also a registered patent attorney, with more than a decade of experience in portfolio development, lifecycle management, and US and international IP law.

The opportunity to join Compass was the natural next step for me on a journey that started in 1999, when I first met Dr. Alexander Shulgin as part of an undergraduate research project. I never would have dreamed that, just 20 years later, I’d have the opportunity to help bring psychedelic innovations to the mental health field.

John Boghossian

John Boghossian

Vice President of Operations

John is Vice President of Operations at COMPASS Pathways. He focuses on daily operations, market access and commercial strategy, partnerships, and fundraising.

Before joining COMPASS Pathways, John attended the Harvard Business School (HBS) for an MBA. During and after his studies, he co-founded a technology company focused on enterprise productivity software. Before HBS, he worked at the Boston Consulting Group (BCG) and specialised in healthcare. He advised global pharmaceutical companies as well as hospital networks across Western Europe and North America. His experience includes R&D strategy, new drug market access strategy, and value-based healthcare outcome measurement. Before BCG, John graduated from the Massachusetts Institute of Technology (MIT) with bachelors in mechanical engineering and economics with distinction, and from the University of Cambridge with a master's degree in Energy Technologies with distinction. An avid traveller, he calls both sides of the Atlantic home.

My goal is to work on a mission-driven early-stage venture with like-minded people. The mission of COMPASS aligns perfectly with my belief in innovative outcome-based healthcare delivery models, in a therapeutic area with significant unmet medical need. I'm excited to be, together with the whole COMPASS team, on the journey to provide new alternatives to mental health disorders like treatment-resistant depression worldwide.

Dr Stephen Wright

Senior Scientific Advisor

Dr Stephen Wright is Senior Scientific Advisor at COMPASS

With over 30 years in pharmaceutical medicine in the UK, France and US, Stephen has played a key role in the development of new therapies for patients, working at Glaxo, at Abbott Laboratories in the US, Beaufour Ipsen, and most recently at GW Pharma, where he was Chief Medical Officer and a main Board Director from 2004 to 2018. Stephen is the author or co-author of more than 100 peer-reviewed research papers, eight review papers, nine case reports, eight book chapters, numerous abstracts and scientific letters, and has presented at and chaired many international meetings. He is a Fellow of the Royal College of Physicians (Edinburgh), a Fellow of the Faculty of Pharmaceutical Medicine, a Fellow of the Royal Society of Medicine, and a Visiting Professor at The University of Reading. Stephen received his Masters degree in Social and Political Science from the University of Cambridge and his medical degree from the University of London. With over 12 years’ experience in clinical medicine, Stephen is a former Consultant Senior Lecturer at The Royal Free Hospital School of Medicine.

I joined COMPASS because I’m passionate about helping companies bring new therapies to the people who need them. I’m proud to support research and regulation for COMPASS, and ultimately advance the management of mental health.

Sue Stansfield

Sue Stansfield

Vice President of Clinical Operations

Sue is Vice President of Clinical Operations at COMPASS Pathways, leading the global clinical trials programme.

Sue gained her PhD in neuroendocrinology in the 1980s and began her career at Wellcome Research Labs, working on the successful registration of Lamictal®. She moved onto Janssen and Parke-Davies in increasingly senior roles in CNS drug development (anxiety, depression, epilepsy, Alzheimer’s Disease). In 1991, Sue joined Quintiles as the Global Project Director leading the development of a reversible inhibitor of monoamine oxidase A (RIMA) towards an NDA (US new drug application) in panic disorder and social phobia with line extension outside USA. From there, Sue pursued a career in the Clinical Research Organisation (CRO) industry that spanned 25 years. She has worked for a number of leading CROs including Quintiles (now IQVIA), PPD, PRA, Premier Research, and inVentiv Health (now Syneos Health), successively expanding her remit with additional functions and regions. At COMPASS Pathways, Sue combines her scientific experience with her trial execution expertise to develop and lead the clinical trials programme.

It is so refreshing to work in such a dynamic team with one single agenda: to overcome the barriers in order to benefit patients.

Amy Lawrence

Amy Lawrence

Director of Communications

More than 15 years’ experience creating and delivering clear, effective and ethical communications for the healthcare industry.

With a degree in biology from the University of Cambridge, Amy’s work has helped to bridge the gap between science, the medical community and the general public. Most notably, she launched the world’s first cervical cancer vaccine, led the global communications for a major oncology brand, and won a SABRE award for the launch of a new treatment for chronic migraine.

Everybody at COMPASS has a genuine passion to help improve mental health. We each have our own story that inspires us; it’s what unites us in our drive to help people live happier lives.

Manon Veraart

Manon Veraart

Director of Business Development

Professional with over 5 years of experience in investment banking and management consulting, and with a background in psychology. At COMPASS Pathways, Manon focuses on operations, investor relations and partnerships.

Prior to joining COMPASS, Manon worked at the Boston Consulting Group (BCG) in London. She joined BCG after graduating from the INSEAD MBA programme (with distinction). During her MBA, she completed an internship at Aleph Capital Partners (investment firm). Before INSEAD, Manon worked first as an Analyst and later as an Associate in the Natural Resources M&A team of Goldman Sachs in London. Manon is originally from the Netherlands and holds master's (with distinction) and bachelor's degrees in Business Administration from Erasmus University (Rotterdam), and a bachelor's degree in Psychology from Leiden University. Manon spent exchange semesters at the University of Southern California, Los Angeles and INCAE, Costa Rica.

I love being part of a highly diverse and collaborative team that is working hard to relieve and solve mental health problems, an issue so many people struggle with. Being able to work on this together, with the ultimate goal of empowering patients globally, motivates me every day.

Alice Gaillard

Alice Gaillard

Manager of Business Development and Operations

Focuses on building business development partnerships and scaling up our operations and fundraising activities.

Before joining COMPASS, Alice was as a Project Leader in the healthcare practice of the Boston Consulting Group, where she worked for 5 years in Paris and London. At BCG she supported global companies, including pharmaceutical and health insurance firms, in devising and implementing growth and operational improvement strategies. Originally from France, Alice studied at HEC Paris School of Management. Passionate about bringing together organisations from the public, private and non-profit sectors to achieve greater social impact, she holds a Master in Management of Private and Public organisations (a double-degree delivered by HEC Paris and Sciences Po Paris).

That individuals and societies can be so unaware and unequipped in facing mental illness, an issue of such magnitude, is in my view the biggest anomaly of our time. I am really excited to be part of a team who inspired me from day one, not only by their fierce commitment to tackle this issue, but also by their holistic and innovative approach in doing so.

Molly Lennard-Jones

Molly Lennard-Jones

Manager of Therapist Training Programme (Europe)

Molly focuses on therapist training and therapist recruitment.

Before joining COMPASS Pathways, Molly studied English Literature at a master's degree level, looking at PTSD in Holocaust Literature. This sparked an interest in mental health research and encouraged her to pursue a career in clinical trials so that she could help translate academic research into real-life treatments, eventually leading her to COMPASS Pathways.

Working at COMPASS, every day brings new challenges; and with that comes the opportunity to learn from a highly motivated and talented team whose primary philosophies are grounded in patient empowerment. Being a part of something that will make positive impacts on the lives of patients is truly incredible.

Kathy Xiang

Manager of Business Development and Operations

Focuses on building business development partnerships, fundraising activities and scaling up our operations.

Prior to joining COMPASS, Kathy was a Consultant at the Boston Consulting Group in London where she worked for 3 years across multiple industries including Healthcare. She has advised both pharmaceutical companies as well as payor/providers on their healthcare strategy. Before BCG she was a corporate solicitor at Cleary Gottlieb Steen & Hamilton LLP in London where she focused on M&A transactions and private equity fund formation. Kathy has a bachelor degree in Law (1st Class) from the University of Law and a bachelor degree in History (1st Class) from the University of Oxford.

There is a real ongoing crisis in mental healthcare today, with a lack of easily accessible and affordable treatments that work. Having seen and felt the impact that this can have on people who are suffering, it is hugely inspiring to be able to work with such an accomplished and motivated team at COMPASS to address that unmet need.

Nisha Thiara

Operations Coordinator

Within the Operations team, Nisha is responsible for the daily management of North American and European clinical research sites as part of our trials.

Nisha is an Operations Coordinator at COMPASS Pathways. She ensures all clinical research sites are fully equipped for upcoming trials and is the first point of contact for trial coordinators at the sites. Nisha graduated from King's College London with a distinction, studying a master's degree in Early Intervention in Psychosis. While at King's, Nisha became increasingly aware of the gaps in treating mental disorders and the real need for innovative patient-centred interventions.

It feels inspiring to be a part of a new wave in treating psychiatric-related disorders. Working in a passionate, driven workplace with bright minds, all working towards accelerating patient access, makes working for COMPASS a truly rewarding experience.

Sam Williams

Samuel I Williams

Project Manager of Clinical Operations (Europe)

Sam focuses on planning, managing, and executing the procedures required for clinical trial progression. 

Sam started working in clinical research during his master’s degree and has been in this line of work ever since. After graduating, Sam worked at PAREXEL and Covance in different project management support roles in clinical technology solutions and clinical operations. Following this, Sam worked in the NHS, in research service delivery. His most recent post before joining COMPASS Pathways was as the Research Manager for the Acute Medicine Directorate at Guy’s and St Thomas’ NHS Foundation trust. There, Sam oversaw and advised different teams, the set-up and management of commercial and non-commercial trials, and research governance across the different clinical services in the directorate.

The innovative approach to therapy, the team of experts and the real drive to empower patients make being part of the COMPASS team truly an amazing experience.

James Wilton

James Wilton

Associate Project Manager of Clinical Operations

James is an Associate Project Manager of Clinical Operations with five years' clinical trial experience.

James worked in research at University College London and University College London Hospitals for eight years. He spent two years as the Clinical Studies Manager at the NIHR-funded Clinical Research Facility, specialising in early-phase and experimental medicine. He also spent one year as the Research Manager of the Arthritis Research UK Centre for Adolescent Rheumatology at UCL, UCLH and GOSH.

I was impressed with the patient-centric approach that COMPASS have to delivering novel therapeutics to tackle an unmet need in mental health.

Monique Superville

Monique Superville

Associate Project Manager of Clinical Operations (North America)

Monique is responsible for managing clinical trials operations across US and Canadian sites.

Prior to joining COMPASS, Monique was the QA/I Manager at NYU School of Medicine where she managed a team of clinical research auditors. Before NYU, she performed clinical research audits as a Senior Human Subjects Protection Analyst at Rutgers University. Prior to Rutgers, she was the Compliance Oversight Manager at Columbia University IRB where she led a clinical research audit team. At all three institutions, the audit activities crossed all medical disciplines. In addition to audits, she assisted researchers with external inspection preparation, study team development and education, and the writing and implementation of Correction and Preventative Action (CAPA) plans. Monique holds a Master of Arts in Applied Psychology from Columbia University and a Bachelor of Arts from The New School for Social Research. She is also a Certified Clinical Research Professional (CCRP).

It’s exciting to be part of a team of talented people with such a broad variety of experience, coming together to accomplish something truly groundbreaking.

Rachel Winzer

Rachel Winzer

Therapist Training Programme Coordinator (North America)

Rachel is responsible for the roll-out and implementation of COMPASS Pathways' therapist training across US and Canadian sites. 

Before joining COMPASS Pathways, Rachel worked as a mental health specialist at the McLean Franciscan inpatient psychiatric unit in Boston, helping patients and their families manage a wide variety of challenges. Before McLean, Rachel was a behavioural treatment counselor at Germaine Lawrence in Boston, a residential treatment centre for adolescents, specialising in trauma and PTSD. Rachel holds a Master of Science in Social Cognition (with distinction) from University College London and a Bachelor of Psychology from University of Colorado Boulder.

Being a part of the COMPASS team and collaborating with like-minded individuals to further human-centered research and improve lives ignites a sense of purpose and passion in me. We are motivated daily by our collective desire to break down barriers to high-quality treatment and combat mental health issues with innovative therapies.

Jess Stuart

Jess Rose Stuart

Therapist Training Programme Coordinator (Europe)

Jess is responsible for ensuring that the COMPASS Pathways therapist training programme runs efficiently across our European trial sites.

Jess graduated from Warwick University with a degree in English and American Literature and developed a passion for psychology by taking part in voluntary work alongside her studies. Jess worked in the media for a number of years before joining a psychology practice, The House Partnership. As Practice Manager, she gained extensive administrative experience in mental health care, acting as the first point of contact for clients seeking talking therapy and enabling the practice to run smoothly on a day-to-day basis.

It is extremely motivating to be part of an accomplished and dedicated team who share the belief that it is possible to end the suffering caused by mental health disorders.

Anais Soula

Anaïs Soula

Research Scientist

Anaïs focuses on the design of the Phase III clinical trial and market access strategy.

After graduating with distinction from a master’s degree in Cellular Biology, Physiology and Pathology at the University of Bordeaux, Anaïs obtained fellowships from the French Ministry of Education and the Fondation pour la Recherche Médicale to carry out her PhD in Molecular Biology and Neuroscience at the Interdisciplinary Institute for Neuroscience. During her PhD, Anaïs explored new ways of communication between brain cells based on the exchange of extracellular vesicles. Keen on integrating cutting-edge science into society, she pursued a master’s degree in Technology and Innovation Management alongside her PhD at the University of Paris-Sud.

At COMPASS, I hope to leverage my scientific background to contribute to the creation of novel treatments for mental health problems.

Lindsey Marwood

Lindsey Marwood

Clinical Research Scientist

Lindsey focuses on the design of clinical studies and the clinical development programme.

Prior to joining COMPASS Pathways, Lindsey managed a clinical trial comparing the clinical and cost effectiveness of augmentation therapies for patients with treatment-resistant depression at King’s College London, where she also completed her PhD in 2017. Her PhD was funded by the Medical Research Council and explored neuroimaging correlates of response to treatment, and the application of novel functional magnetic resonance imaging methods in patients with depression and anxiety.

I have seen first-hand from working with patients that there are gaps in current treatments for mental illness. I am passionate about bringing new and promising treatments to the market for mental illness to improve outcomes for patients.

Shaun Hurley

Shaun Hurley

Research Scientist

Shaun focuses on the design of preclinical studies and the clinical development programme.

Prior to joining COMPASS Pathways, Shaun received a scholarship from the Guy's and St. Thomas Trust Charity that allowed him to undertake both an MRes in Biomedical and Translational Sciences and a PhD in Neuroscience at King's College London. During his PhD, in which he studied the role of an autism-associated gene in brain development and function, Shaun also travelled to research institutes in the US and Italy to apply cutting-edge techniques to his research.

I was inspired to join COMPASS because of the team's ambition to combine a patient-centred approach with scientific rigour and innovation. It is highly motivating to apply these principles to mental health disorders that have significant unmet clinical need.

Tobias Whelan

Research Associate

Focuses on the design of both preclinical and clinical studies within the clinical development programme.

Prior to his role as a Finance Executive and before joining COMPASS Pathways, Tobias completed his MSci in Neuroscience at the University of Southampton. His research projects involved the investigation of autism spectrum disorder in addition to novel therapeutic interventions in mental health. During his thesis, Tobias used genetic engineering techniques to study the role of an autism-associated gene on behaviour.

COMPASS provides the opportunity for innovation within a collaborative environment, driving improved treatment options for disorders of considerable unmet need with a patient-centric approach.

Sarah Drummond

Sarah Drummond

Executive Assistant

Sarah is an Executive Assistant with over 20 years’ experience.

Before joining COMPASS Pathways, she spent 10 years working as George Goldsmith’s Executive Personal Assistant at Tapestry Networks, a company dedicated to bringing together leaders from business and institutions to help make the world better by making it run better.  During her time as an Executive Assistant, she has worked in a number of different sectors in London including surveyors, media, finance, consulting, and professional services.

I believe COMPASS can make a real and positive difference to the unmet medical needs surrounding mental health and well-being.

Tina Gibbard

Tina Gibbard

Personal Assistant

Tina is responsible for providing a productive work environment for the COMPASS team.

Tina's roles prior to joining COMPASS Pathways were as Personal Assistant and Project Manager in a diverse mix of industries - media, property and digital development. She also spent time as an artist, having gained a Postgraduate Diploma in Fine Art from the Chelsea College of Art and Design.

I joined COMPASS as it is an incredible opportunity to be involved in the advancement of groundbreaking treatment for psychiatric-related disorders.

Board of Directors

Ekaterina Malievskaia

Ekaterina Malievskaia MD MScPH

Chief Innovation Officer and Co-Founder

Dr Ekaterina Malievskaia leads Research and Development at COMPASS.

Ekaterina received her medical degree from St Petersburg Medical Academy in St Petersburg, Russia. After her Internal Medicine residency training, she completed an Environmental Medicine Fellowship at Mount Sinai School of Medicine and received her MSc in Public Health from New York University Medical School. She worked in private practice, academic medicine and public health for more than 15 years in the greater New York area. She was a Clinical Instructor of Medicine at Mount Sinai School of Medicine, as well as a Research Professor at City University of New York.

After moving to London in 2011, Ekaterina worked in global health and medical philanthropy, focusing on improving outcomes in maternal and child health. She founded COMPASS Pathways with her husband George Goldsmith in 2016, having experienced at first hand the challenges in accessing evidence-based and effective mental health care for a family member.

We have created COMPASS to improve patients’ access to innovation in mental health. Through our personal experiences, we have learned how challenging it could be to find the right treatment and right expertise in time. We also learned that it could make all the difference in the outcomes. We walked that path so others don’t have to.

George Goldsmith

George Goldsmith

Executive Chairman, Chief Executive Officer and Co-Founder

George is an entrepreneur dedicated to bringing about positive change in society with particular focus on health and wellbeing.

George's early training and experience was a multi-disciplinary blending of cognitive psychology, clinical psychology and computer science. His first company, The Human Interface Group, was a pioneer in collaborative software and acquired by Lotus Development. George led the Lotus Institute and developed software and services to support high-performance, distributed teamwork. George then created TomorrowLab, which provided strategic guidance to internet businesses in the late 1990s. At the same time, he became a senior advisor to McKinsey & Company’s leadership, and eventually joined McKinsey as CEO of TomorrowLab@McKinsey. Subsequently, as a member of the Young Presidents Organisation (YPO) and its International Board of Directors, George founded YPO Networks. In 2002, George founded Tapestry Networks, an organisation committed to improving leadership performance and governance effectiveness in regulated sectors. He still serves as Tapestry Networks' Non-Executive Chairman. George also serves on the board of directors for AnaBios, a company redefining drug discovery. He and his wife, Ekaterina Malievskaia MD, live in London.

I have spent my life working with teams of leaders seeking to do extraordinary things. The best of them fight the tendency to accept zero-sum strategies and declare victory. They understand that we can create environments where people suspend disbelief, build trust and chase unlikely combinations of new ideas and technologies.

Annalisa Jenkins

Annalisa Jenkins MBBS

Independent Director

Annalisa is a senior biotech executive, the Executive Chairman at Vium, and a Non-Executive Director at eight other biotech companies.

Annalisa was previously Head of R&D at Merck Serono and Global Medical Senior Vice-President at Bristol-Myers Squibb. She is the CEO of PlaqueTec, a company driving the future of personalised medicine in coronary artery disease, in addition to chairing or serving on the boards of a number of private and public companies in the life sciences industry, located in the US and the UK.
Thomas Lönngren

Thomas Lönngren

Independent Director

Thomas Lönngren is a senior regulatory Executive, and served as Executive Director of the European Medicines Agency (EMA) from 2001-2010.

Thomas is currently Director at Pharma Executive Consulting and Strategic Advisor at the NDA Group. His greatest achievement is heading the European Medicines Agency for 10 years, taking it from a relatively unknown agency in 2001 to become recognised together with the US FDA as a world leader in drug regulation. Based on his extensive experience and knowledge of drug and device regulation, approval, market access, management, strategy and leadership, he currently advises pharmaceutical companies worldwide on drug development with a focus on regulatory and market access. He also serves as a non-executive board member, participates in scientific Advisory Boards and frequently speaks at conferences around the world.
David Norton

David Norton

Independent Director

David Norton is a senior Biopharma Executive, and the former Company Group Chairman of Global Pharmaceuticals at Johnson & Johnson.

David is currently a Director at two other life sciences companies. He has also been a standout as Board member and benefactor of Alliance For Aging Research, a national non-profit organisation, which seeks research-based, innovative solutions to the health problems of aging populations.
Florian Brand

Florian Brand

Member of Board of Directors and Founding Seed and Series A Investor

Florian is the Co-Founder and Chief Executive Officer of ATAI Life Sciences AG, a Seed and Series A investor in COMPASS Pathways.

Florian focuses on the operational execution of early-stage discovery and drug development programmes. He is currently interim CEO at Perception Neuroscience, one of ATAI's platform companies. ATAI is a global biotech company builder that leverages a decentralised, technology- and data-driven platform model to serve millions of people suffering with mental health disorders. Prior to ATAI, Florian was Co-founder and MD at Springlane, a growing technology company in the German consumer space. His past experiences include roles at Rocket Internet, Allianz, and the Tanzanian German Programme to Support Health. Florian studied economics and management.

We know that the unmet medical need of depression is increasingly urgent. With more than 300 million people living with depression worldwide – a third of whom do not respond to standard treatments – we cannot wait to take action. Together with COMPASS and other leaders in the field, ATAI is committed to bridging the gap between what people living with mental health illnesses need, and what the system can currently provide.

Paolo Siviero

Paolo Siviero

Member of Board of Directors and Series A Investor

Paolo is Head of Investments for Principia III, the first Italian VC and PE fund entirely dedicated to life sciences investments, and formerly Head of Strategy and Policy on Medical Products Area at AIFA (Italian regulator).  

At Agenzia Italiana del Farmaco (AIFA), Paolo was responsible for establishing prices and refundability of medicines, evaluating HTAs and checking pharmaceutical expenditures. Prior to joining AIFA, he was Chairman of MEDEV Group and a Board Member of the European Medicines Agency (EMA). Paolo has extensive experience investing in life sciences companies, including AnaBios, Enterome, and Ixaltis. For more information about Principia, please visit their website: https://principiasgr.it/
Srini Rao

Srinivas Rao, MD, PhD

Member of Board of Directors and Series A Investor

Srinivas Rao is the Chief Scientific Officer at ATAI Life Sciences AG and the former CEO of Kyalin Biosciences.

Srinivas Rao has been the Chief Medical Officer of multiple biotech companies, including Axial Biotheraputics, Inc, Deposed, Inc and Kayla Pharmaceuticals. He holds an MD in Internal Medicine from Yale University School of Medicine and a PhD in Neuropharmacology from Yale University. Srinivas has also been an advisory board member to UCSD SDTA and HUYA Bioscience International.  

Scientific Advisory Board

David Nutt

Prof David Nutt DM FRCP FRCPSYCH FSB FMEDSCI

Chair of Scientific Advisory Board

Professor David Nutt is the Edmond J Safra Chair in Neuropsychopharmacology at the Imperial College London. He is also the President of the European Brain Council, and the former President of the European College of Neuropsychopharmacology.

Professor Nutt is a British neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep. He was until 2009 a professor at the University of Bristol heading their Psychopharmacology Unit. Since then he has been the Edmond J Safra chair in Neuropsychopharmacology at Imperial College London and director of the Neuropsychopharmacology Unit in the Division of Brain Sciences there. Nutt was a member of the Committee on Safety of Medicines, and was President of the European College of Neuropsychopharmacology. His book Drugs Without the Hot Air (UIT press) won the Transmission Prize for Communicating Science in 2014.

Prof Sir Alasdair Breckenridge CBE FRSE

Member of Scientific Advisory Board

Alasdair Breckenridge was Chairman of the Medicines and Healthcare products Regulatory Agency which was formed in April 2003 by the merger of the Medicines Control Agency and the Medical Devices Agency.  Previously he was Chairman of the Committee on Safety of Medicines and Professor of Clinical Pharmacology in the University of Liverpool. He is now Chairman of the Advisory Board of the Centre of Regulatory Excellence of Duke/NUS in Singapore. He was knighted in 2004. 

During his tenure at MHRA, Sir Alasdair served as the first Chair of the Department of Health’s Emerging Science and Bioethics Advisory Committee (ESBAC), an organisation responsible for providing advice to UK health departments on emerging healthcare scientific developments and their ethical, legal, social and economic implications. He was a member of the Medical Research Council and he worked closely on several programmes of the European Union, the World Health Organisation and the International Union of Pharmacology and as Chair of the Committee on Safety of Medicines.  

As a regulator, I am intrigued by the possible use of a drug with a previously uncertain reputation in a novel situation and how the regulatory hurdles could be overcome. To take a drug from the 1950s and reposition it in modern medicine especially for an unmet medical need presents a series of fascinating challenges.

Robin L Carhart-Harris

Robin L Carhart-Harris PhD

Member of Scientific Advisory Board

Dr Robin Carhart-Harris is Director of the Centre for Psychedelic Research at Imperial College London.

Dr Carhart-Harris moved to Imperial College London in 2009 after obtaining his PhD in Psychopharmacology from the University of Bristol, and prior to that, an MA in Psychoanalysis at Brunel University. At Imperial, he has worked on a series of brain imaging studies into the brain effects of psilocybin, MDMA, LSD and DMT, and two clinical trials of psilocybin for depression. In 2015 he founded the Psychedelic Research Group at Imperial, which he runs. He has an honorary position at the University of Oxford.

I admire COMPASS's vision and ability not just to talk but to deliver. For the sake of patient access, I hope and believe they will succeed and am keen to help them actualise this.

Thomas Insel

Tom Insel MD

Member of Scientific Advisory Board

Thomas Insel MD is a psychiatrist and neuroscientist who served as Director of the US National Institute of Mental Health (NIMH), Professor of Psychiatry at Emory University and founding director of the Center for Behavioral Neuroscience in Atlanta.

Tom is a psychiatrist and neuroscientist. Between 2002 and 2015, he served as Director of the US National Institute of Mental Health (NIMH), the component of the US National Institutes of Health (NIH) committed to research on mental disorders. Prior to that, he was Professor of Psychiatry at Emory University where he was founding director of the Center for Behavioral Neuroscience in Atlanta. He led the mental health team at Verily (formerly Google Life Sciences) from 2015 to 2017. He is also a member of the US National Academy of Medicine and has received numerous national and international awards including honorary degrees in the US and Europe. He is currently Co-founder and President of Mindstrong Health.  

Mental health care needs innovation. The traditional model of care delivery is often built around the needs of providers and payers not the preferences of patients and families. As a result, most people with mental illness avoid getting care. When they seek help, patients are likely to receive medications, psychosocial therapies, or devices but not an integrated plan that provides all the potential interventions in a personalised, evidence-based approach. The COMPASS medication-assisted psychotherapy strategy is innovative in that it integrates medication and psychotherapy; and it is disruptive by offering patients a treatment that many people prefer. I have chosen to be involved with COMPASS Pathways because I believe that this approach has potential but needs to be validated in rigorous, controlled clinical trials. My goal is to help COMPASS Pathways set a high bar for science so that, should the data be supportive, patients and families can trust that medication-assisted psychotherapy is an evidence-based approach.

Diego Pizzagalli

Diego Pizzagalli PhD

Member of Scientific Advisory Board

Diego Pizzagalli is an experimental psychologist and neuroscientist. He is a Professor of Psychiatry at the Harvard Medical School. At the McLean Hospital, he is the Director of the McLean Imaging Center, the Director of the Center for Depression, Anxiety and Stress Research, the Director of Research at the Division of Depression & Anxiety Disorders, as well as the Director of the Laboratory for Affective and Translational Neuroscience.

Between 2002 and 2010, he was a faculty member in the Department of Psychology at Harvard University. In 2010, he was recruited in McLean Hospital to serve as the Founding Director of the newly established Center for Depression, Anxiety and Stress Research (CDASR), as well as the Director of the McLean Imaging Center (MIC). Since September 2015, he also serves as the Director of Research for the Division of Depression and Anxiety. He is currently a Professor of Psychiatry at Harvard Medical School. The main goals of his research are to improve our understanding of the psychological, environmental, and neurobiological factors associated with mood disorders, particularly major depression. To this end, he integrates behavioral, electrophysiological, neuroimaging, and, more recently pharmacological, approaches to investigate three putative endophenotypes of depression: anhedonia (loss of pleasure), increased stress sensitivity, and executive dysfunction. Dr Pizzagalli has published over 170 papers and chapters and serves on the editorial board of 10 journals. Among several awards, he received the Distinguished Scientific Award for an Early Career Contribution to Psychophysiology from the Society for Psychophysiological Research (2006), the Early Career Award from the EEG and Clinical Neuroscience Society (2007), a MERIT award from the National Institute of Mental Health (2016), the Joel Elkes Research Award from the American College of Neuropsychopharmacology (2017), and a NARSAD Distinguished Investigator Award (2018).

Currently available antidepressant treatments (eg medications, evidence-based psychotherapy) work well for many individuals, but up to 45% of individuals with major depression fail to respond to available interventions. Thus, there is an acute unmet need to develop novel treatment strategies for our patients.

Augustus John Rush

John Rush MD

Member of Scientific Advisory Board

Dr Rush is a professor of psychiatry with positions including Professor Emeritus at Duke-National University of Singapore (Duke-NUS) and CEO of Curbstone Consultant LLC.

John's 45-year academic career has focused on the psychology and biology of mood disorders. His work has led to the development and evaluation of innovative treatments (medications, somatic treatments, psychotherapy), disease management protocols and clinical tools to improve early detection and care for persons with mood disorders and their families. He is the author of more than 800 professional publications and the recipient of numerous awards. He was recognised as one of the “World’s Most Influential Scientific Minds” by Thomson Reuters in 2014.

The focus on improving the treatment of depression, the rigorous scientific approaches being considered and the quality of the scientific team being formed were important elements in my consideration to join COMPASS, as was the strong commitment of the COMPASS leadership. The development and rigorous testing of the potential antidepressant effects of psilocybin, if successful, would be a scientific and therapeutic paradigm-changing contribution, opening new avenues to additional treatment innovations for other neuropsychiatric conditions. The opportunity to make this kind of contribution is a rare privilege.

Alan Schatzberg

Prof Alan Schatzberg MD

Member of Scientific Advisory Board

Director at the Stanford Mood Disorders Center and Professor of Psychiatry at the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine.

Alan Schatzberg MD has been the Kenneth T Norris, Jr Professor of Psychiatry and Behavioral Sciences at Stanford University School of Medicine since 1991. He previously served as the President of the American College of Neuropsychology, the Society of Biological Psychiatry, and the American Psychiatric Association (APA). From 1991 to 2010, Alan served as the Chair at Stanford University School of Medicine, Psychiatry, and Behavioural Sciences. He has published over 362 publications, 98 of which are featured publications holding significance in the academic field. He is also the co-editor-in-chief of the Journal of Psychiatric Research. Alan has received multiple national and international awards and honours, including the Judd Marmor Award for Biopsychosocial Research and the Distinguished Service in Psychiatry Award from the American Psychiatric Association (2018), the Lifetime Achievement Award from the International Society of Psychoneuroendocrinology (2015), and the Society of Biological Psychiatry Gold Medal Award (2015). He is a member of THE Bio-X and Wu Tsai Neurosciences Institute. Alan earned his medical degree from Harvard University, before completing his medical training at the New York University of Medicine. He is board-certified in psychiatry and holds a fellowship granted by Harvard Medical School.
Paul Summergrad

Prof Paul Summergrad MD

Member of Scientific Advisory Board

Prof Paul Summergrad MD is the Dr Frances S Arkin professor and chairman of the Department of Psychiatry, professor of medicine at Tufts University School of Medicine, and psychiatrist-in-chief at Tufts Medical Center. He is the past president of the American Psychiatric Association. 

Paul has served as founding chairman of the Tufts Medical Center Physicians Organization since 2005 and is a former president of the American Psychiatric Association (APA) and of the American Association of Chairs of Departments of Psychiatry. He is a member of the Tufts Medical Center and the Wellforce boards of trustees, and co-chairs the Tufts University Mental Health Task Force.

An international leader in medical psychiatric illness and care, his research focuses on mood disorders, medical-psychiatric illness, and health system design. He has published extensively with more than 100 peer review publications, books, book chapters and other communications. He serves on the editorial boards of Academic Psychiatry, Current Psychiatry and Personalized Medicine in Psychiatry. A sought-after speaker, educator and consultant, he has served as a visiting professor and been invited to give lectures across the world. He is a member of the Diagnostic and Statistical Manual 5 Steering Committee of the American Psychiatric Association and the Standing Committee on Nominations of the World Psychiatric Association. He is a distinguished fellow of the American Psychiatric Association, a fellow of the American College of Psychiatrists and of the American College of Physicians, and has received numerous other awards and honours including Castle and Connolly’s America’s Top Doctors from 2011 to the present, and the Distinguished Faculty Award from Tufts University School of Medicine.

Paul earned his degree from the School of Medicine at the State University of New York, before completing his training in internal medicine at Boston City Hospital and Boston University School of Medicine and in psychiatry at Massachusetts General Hospital and Harvard Medical School, where he was chief resident and a clinical fellow in psychiatry. He is board-certified in both psychiatry and internal medicine.

The limitations of currently available treatments for psychiatric illnesses has led to investigating agents which have been previously abandoned or used for other purposes. Recent pilot research has suggested a possible benefit for some psychoactive agents. Given the complex history of these agents, it requires great care and highly responsible leadership to do larger scale clinical studies. The leadership of COMPASS Pathways brings extraordinary skills and experience. Their track record of entrepreneurship, clinical excellence and rigorous attention to oversight of complex endeavors convinced me that they would be able to pursue this research in a manner which would reflect both the opportunities and challenges in finding new treatments for refractory psychiatry disorders.

Kirk Rutter

Kirk Rutter

Special Advisor, Patient Experience

Kirk is a technologist for a London University. He became a volunteer patient on the 2015 Imperial College clinical study of psilocybin therapy for treatment-resistant depression (TRD). 

Driven by the scheduled status of psilocybin that limits its use in research, Kirk talks openly about his experience with depression and the profound beneficial long-lasting effects of psilocybin therapy following the trial.

As one of the few people who have received this treatment, I fully appreciate the potential of psilocybin therapy for use with treatment-resistant depression. Shortly after the trial I remember thinking it was shocking that this treatment might never be widely available. I first met COMPASS to record a short film to talk about my experience. I was struck by their professionalism, ethics and commitment to patients.

Investors

Founding Seed Investors

ATAI Life Sciences is an internationally active biotech company investing in and acquiring therapeutics focusing on longevity and mental wellbeing. Galaxy Investment Partners, one of our Seed investors, has joined forces with ATAI on their COMPASS investment.

Thiel Capital provides strategic and operational support for Peter Thiel’s many investment initiatives and entrepreneurial endeavours.

Series A Investors

ATAI Life Sciences is an internationally active biotech company investing in and acquiring therapeutics focusing on longevity and mental wellbeing.

Principia SGR is one of the leading Italian Venture and Growth Capital funds focused on healthcare and life sciences.

Subversive Capital is dedicated to investing in radical companies whose core missions subvert the status quo and require sophisticated government and regulatory strategies for success.

Thiel Capital provides strategic and operational support for Peter Thiel’s many investment initiatives and entrepreneurial endeavours.

Others

Other investors include prominent investment entities (eg funds, family offices) and individuals.